Inno Bio Ventures and Cevec sign licensing agreement
Malaysian contract manufacturer Inno Biologics, a subsidiary of Inno Bio Ventures, has signed a licensing agreement with Cevec Pharmaceuticals, a German developer of a human expression system derived from amniocytes.
Malaysian contract manufacturer Inno Biologics, a subsidiary of Inno Bio Ventures, has signed a licensing agreement with Cevec Pharmaceuticals, a German developer of a human expression system derived from amniocytes.
Inno Biologics will use Cevec's CAP technology to develop a cell line for the production of biopharmaceuticals.
The CAP cell line is said to offer stable and higher expression of human proteins and cell density than existing production technology. The cell's origins are ethically accepted with a complete cell source and cell line development documentation. Most importantly, Inno says the CAP human cell line will provide the company with non-oncogenic cells, which will ensure that future therapies can be delivered in a safe and effective manner.
"After launching our new cell line in the US and European market we are delighted to have now our first customers in Asia/Pacific working with our cells. With expression rates and protein quality outperforming any other human system on the market we are proud to have Inno Biologics working with our unique, state of the art cell line," said Wolfgang Kintzel, managing director of Cevec.
"Because post-translational modifications play a significant role for the bioactivity of recombinant proteins it is very important to produce proteins with human-like glycosylation and sialylation," added Rainer Lichtenberger, ceo of Cevec.
Inno Bio Ventures" group md Dato" Mohd Nazlee Kamal said the company was looking forward to using Cevec's technology to produce a better drug in the future.
Inno Biologics claims its biomanufacturing facility in Nilai Negeri Sembilan is the first cGMP biopharmaceutical complex in Malaysia.
Inno Biologics is also the first Asian company to sign a cooperation agreement with Boehringer Ingelheim, Germany, whereby Inno Biologics" clients will have access to BI's manufacturing technology platform for Phase I and Phase II biopharmaceutical products that are made using mammalian cell culture.